Effect of anti–tumor necrosis factor α therapy on the progression of subclinical atherosclerosis in severe rheumatoid arthritis
about
Atherosclerosis in early rheumatoid arthritis: very early endothelial activation and rapid progression of intima media thickness.Validated methods for assessment of subclinical atherosclerosis in rheumatology.Accelerated atherosclerosis in systemic lupus erythematosus: role of proinflammatory cytokines and therapeutic approaches.The ZC3HC1 rs11556924 polymorphism is associated with increased carotid intima-media thickness in patients with rheumatoid arthritisStudy of association of CD40-CD154 gene polymorphisms with disease susceptibility and cardiovascular risk in Spanish rheumatoid arthritis patients.Systemic inflammation and cardiovascular risk factors predict rapid progression of atherosclerosis in rheumatoid arthritis.SMAD3 rs17228212 gene polymorphism is associated with reduced risk to cerebrovascular accidents and subclinical atherosclerosis in anti-CCP negative Spanish rheumatoid arthritis patients.New insights into the functional role of the rheumatoid arthritis shared epitope.Lack of association between JAK3 gene polymorphisms and cardiovascular disease in Spanish patients with rheumatoid arthritis.Correlation between endothelial function and carotid atherosclerosis in rheumatoid arthritis patients with long-standing diseaseCCR5Δ32 variant and cardiovascular disease in patients with rheumatoid arthritis: a cohort studyProtective Role of the Interleukin 33 rs3939286 Gene Polymorphism in the Development of Subclinical Atherosclerosis in Rheumatoid Arthritis Patients.What effects might anti-TNFalpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFalpha in cardiovascular pathophysiology.Lack of association between TLR4 rs4986790 polymorphism and risk of cardiovascular disease in patients with rheumatoid arthritisAnti-TNF-alpha-adalimumab therapy is associated with persistent improvement of endothelial function without progression of carotid intima-media wall thickness in patients with rheumatoid arthritis refractory to conventional therapy.Predictors of new atherosclerotic carotid plaque development in patients with rheumatoid arthritis: a longitudinal study.CARD8 rs2043211 (p.C10X) polymorphism is not associated with disease susceptibility or cardiovascular events in Spanish rheumatoid arthritis patientsEffect of 1-year anti-TNF-α therapy on aortic stiffness, carotid atherosclerosis, and calprotectin in inflammatory arthropathies: a controlled studyCardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs.Influence of elevated-CRP level-related polymorphisms in non-rheumatic Caucasians on the risk of subclinical atherosclerosis and cardiovascular disease in rheumatoid arthritis.Infliximab improves vascular stiffness in patients with rheumatoid arthritis.Lack of association between ABO, PPAP2B, ADAMST7, PIK3CG, and EDNRA and carotid intima-media thickness, carotid plaques, and cardiovascular disease in patients with rheumatoid arthritis.Cardiovascular disease risk in rheumatoid arthritis: progress, debate, and opportunity.Can suppression of inflammation by anti-TNF prevent progression of subclinical atherosclerosis in inflammatory arthritis?Cardiovascular risk and the use of biologic agents in rheumatoid arthritis.Effects of TNFα inhibitors on adiposity and other cardiovascular risk factors: implications for the cardiovascular prognosis in patients with rheumatoid arthritis.Tofacitinib improves atherosclerosis despite up-regulating serum cholesterol in patients with active rheumatoid arthritis: a cohort study.Clinical significance of brachial flow-mediated dilation in patients with rheumatoid arthritis.Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis.The effects of golimumab on subclinical atherosclerosis and arterial stiffness in ankylosing spondylitis—a randomized, placebo-controlled pilot trial.Systemic immunosuppression and risk of age-related macular degeneration
P2860
Q34153114-DFC022B0-EE7F-4D17-B185-C4101856B213Q34164481-66070CB7-7DF9-4F5A-ACC0-3B21BB453402Q34170097-305706E8-53CC-43C8-809D-71ECD139F6ADQ34388576-6F2E56CE-87D1-4A62-940A-13072067432DQ34482096-141C9927-6B03-40B7-9CA6-5839F0DF87D6Q34550743-5FC1F70C-77C6-418E-8B9C-F5F9D1948C1CQ35035496-0F5E9DFE-46DC-41E7-A9AC-BE92E17ED382Q35156717-156FF26C-209F-4EBA-89B3-98E2875A53EAQ35178124-8E7C13CA-E7BC-43DA-8065-0832133775C5Q35557952-E03CE9F7-B855-4FA1-BB7F-32C0312314B1Q35617726-9780E24C-5ABB-4813-907C-7158C2496619Q35842035-3EBA9388-0F36-4F46-A0E4-FF8A6B40B0AAQ35954625-BA3815AB-DAAD-49BB-90E9-65EE3E63335FQ36081372-629FECC5-66D8-46C8-A138-8990908AB69EQ36151574-729E43E3-27E2-45EA-93AB-8D9B6E231951Q36245670-33676471-FEFC-4C49-B5CA-718EB1EB0D85Q36490766-64A60403-7712-4632-8A28-235FD6659440Q36792775-6957A51D-D086-4E16-8F17-30D577E30BC3Q37142052-2198069D-D9B6-4508-800F-561AE6A564A3Q37184930-EF4CE6F9-16F2-441A-802B-CAB603B60AF7Q37245192-F02D0A29-F816-4925-B6E6-C5A78B17AEB1Q37699878-D03E3A5B-37CF-4AF2-ADC0-0BBAFAC25042Q37859676-EFB8DF95-05D4-404D-BB91-CA89FD70C63DQ38185646-1AEE3550-C3CA-441F-8D34-A68E9398804BQ38260198-7A621B6D-7CD0-4B55-AC99-58371D98CBD6Q38323310-371631F5-0591-4CF7-A24B-0EF407119FBDQ42696887-16B345CE-6AEF-4641-BA70-063AFDAC214BQ43581222-B336193C-47A6-4025-92DB-1F624BA918BDQ44293608-BF708DAA-6759-4F51-B156-80036D17575EQ53095551-50A96D25-18F1-4368-BF33-DAB57E834ACDQ58713704-7647D9F7-0D0E-442C-88C8-4D46D25C72D8
P2860
Effect of anti–tumor necrosis factor α therapy on the progression of subclinical atherosclerosis in severe rheumatoid arthritis
description
wetenschappelijk artikel
@nl
наукова стаття, опублікована у 2006
@uk
name
Effect of anti–tumor necrosis ...... in severe rheumatoid arthritis
@en
Effect of anti–tumor necrosis ...... in severe rheumatoid arthritis
@nl
type
label
Effect of anti–tumor necrosis ...... in severe rheumatoid arthritis
@en
Effect of anti–tumor necrosis ...... in severe rheumatoid arthritis
@nl
prefLabel
Effect of anti–tumor necrosis ...... in severe rheumatoid arthritis
@en
Effect of anti–tumor necrosis ...... in severe rheumatoid arthritis
@nl
P2093
P921
P356
P1476
Effect of anti–tumor necrosis ...... in severe rheumatoid arthritis
@en
P2093
Carlos Garcia-Porrua
Carlos Gonzalez-Juanatey
Javier Llorca
Miguel A. Gonzalez-Gay
P304
P356
10.1002/ART.21707
P577
2006-01-01T00:00:00Z